
Welcome to the sDHT Adoption Library, featuring NaVi
NaVi is a closed-environment AI research assistant that leverages a carefully curated library of more than 300+ vetted documents, including FDA guidance and industry best practices. NaVi helps you search and explore content across the sDHT Adoption Library and Roadmap using natural language questions.
The Library is intended to serve as a living resource. Content is added periodically as new guidance, standards, and peer-reviewed research are released.
Meet NaVi: Your AI-Powered Research Assistant
Library scope and selection
To ensure high-quality, relevant results, the Library follows a predefined scoping approach:
- Inclusions: FDA guidance, non-commercial standards, and peer-reviewed research (2018–Present) focused on sDHTs being used as measurement tools for medical products in U.S.-based clinical trials.
- Exclusions: Materials from single commercial entities, non-U.S. regulatory bodies (except select EMA guidances with direct U.S. cross-relevance), and conference proceedings, and conference proceedings.
Inclusion in the Library does not imply endorsement, completeness, or regulatory acceptability.
Library scope
Resources in the sDHT Adoption Library are identified using a predefined scoping approach and include publicly available FDA guidance, non-commercial standards and guidance, and peer-reviewed research relevant to sDHT use in U.S.-based clinical trials. Materials from single commercial entities, non-U.S. regulatory bodies, conference proceedings, and studies conducted exclusively outside the United States are excluded; inclusion does not imply endorsement or regulatory acceptability.
Last updated 2026: Library content is reviewed and updated on a periodic basis as new eligible materials become available.
Novel Endpoints Interactive Selection Tool
Novel Endpoints Interactive Selection Tool
Patient-centeredness is a key criterion, with higher importance assigned to endpoints identified by patients as meaningful.
The tool includes predefined weighting criteria to ensure that endpoints addressing unmet needs are prioritized.
A structured rating scale facilitates the comparison of novel endpoints across different therapeutic areas.
Digital measurement technologies, such as wearables and ePROs, are increasingly considered viable novel endpoints.
The tool provides a standardized approach to endpoint selection but requires user input to tailor scores to specific trial needs.
Recommendations
Clinical researchers should use the tool to systematically evaluate novel endpoints before incorporating them into study designs.
Weighting criteria should be adapted based on the specific therapeutic area and patient population to reflect real-world priorities.
Endpoint selection should incorporate regulatory and scientific considerations to ensure alignment with study objectives.
Digital health technologies should be leveraged where appropriate to support novel endpoint validation and implementation.
Stakeholder engagement, including patient advocacy groups, should be integrated into the endpoint selection process.
Regulatory Considerations
Novel endpoints should align with FDA and regulatory body expectations for evidence generation and validation.
The tool does not replace regulatory guidance but can serve as a structured framework for early-phase endpoint assessment.
Sponsors should document endpoint selection rationale in submissions to regulatory agencies.
Digital health endpoints should comply with data integrity and privacy regulations, including HIPAA and GDPR.
Ongoing validation and post-market evidence generation may be required for novel digital endpoints used in pivotal trials.
Some summaries are generated with the help of a large language model; always view the linked primary source of a resource you are interested in.
Objectively Measured Physical Activity in Patients with COPD: Recommendations from an International Task Force on Physical Activity
Objectively Measured Physical Activity in Patients with COPD: Recommendations from an International Task Force on Physical Activity
There is a wide variability in PA measurement methodologies in existing literature, which complicates comparisons across studies.
The use of digital tools like activity monitors complicates the regulatory process due to non-interchangeability and varying technical and regulatory requirements.
There is a need for standardized procedures to ensure data comparability and integrity.
Recommendations
Implement a standardized methodology for PA data collection and reporting.
Use a standard operating procedure for data collection regarding PA outcomes.
Ensure that activity monitors meet safety, usability, and acceptability criteria for COPD patients.
Encourage widespread adoption of the proposed recommendations to facilitate further research.
Consider device agnosticism while ensuring device sensitivity and accuracy.
Regulatory Considerations
Devices should be device agnostic but must ensure sensitivity, accuracy, and data verification.
Regulatory requirements vary across jurisdictions and need to be met for device approval.
Safety, usability, and acceptability of devices for COPD patients are critical criteria.
Some summaries are generated with the help of a large language model; always view the linked primary source of a resource you are interested in.